Long acting risperidone in treatment of schizophrenia: A retrospective study;Şizofreni tedavisinde uzun etkili risperidon: Geriye dönük bir çalişma

Klinik Psikofarmakoloji Bulteni

Volumn 17, Issue 3, 2007, Pages 119-123

  Yumru, Mehmet ^a   Savaş, Haluk A ^a   Kokaçya, M Hanifi ^a   Virit, Osman ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Efficacy; Long acting risperidone; Schizophrenia

Indexed keywords

LONG ACTING DRUG; RISPERIDONE;

AKATHISIA; ARTICLE; DRUG EFFICACY; DYSKINESIA; FOLLOW UP; HUMAN; OCULOGYRIC CRISIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 34548803109     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006; 67: 1542-1550
2. Yumru M, Savaş HA, Cansel N, Özen ME, Kandemir H. Nöroleptik malign sendrom ve nöropsikiyatrik sekelleri: Geriye dönük bir araşrma. Klinik Psikofarmakoloji Bülteni 2006; 16: 31-34
3. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patient with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long acting risperidone. Eur Psychiatry 2004; 19: 219-225
4. Savas HA, Yumru M, Selek S, Kaya MC. Atypical antipsychotics as "mood stabilizers": a retrospective chart review. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1064-1067
5. Yumru M, Savas HA, Selek S, Savas E. Acute Dystonia After An Initial Dose of Ziprasidone: A Case Report. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 745-747
6. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savafl E, Oral ET, Atagün İ. Atypical Antipsychotics Related Metabolic Syndrome In Bipolar Patients. J Affect Disord 2007; 98: 247-252
7. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic Malignant Syndrome Induced By Ziprasidone On The Second Day of Treatment: A Case Report. World J Biol Psychiatry 2007; 8: 42-44
8. Love RC, Conley RJ. Long acting risperidone injection. Am J Health-Syst Pharm 2004; 61: 1792-1800
9. Ebrinç S, Başoǧlu C, Çetin M, Filiz M, Şendoǧan N. Şizofrenili hastalarda haloperidol ve risperidonun klinik etki ve yan etkileri. Klinik Psikofarmakoloji Bülteni 2002; 12: 6-13
10. Yazici AE, Yazici K, Taneli B, Tot Ş, Kanik A. Şizofreni tanisi almiş hastalarin tedavisinde olanzapin ve risperidonun etkililiǧinin karşilaştirilmasi: Bir açik klinik çalişma. Klinik Psikofarmakoloji Bülteni 2002; 12: 115-120
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4.baski, Washington DC, American Psychiatric Association 1994: 739-742
12. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
13. Kostakoǧlu AE, Batur S, Tiryaki A. Pozitif ve Negatif Sendrom Ölçeǧinin (PANSS) Türkçe Uyarlamasinin Geçerlik ve Güvenilirliǧi. Türk Psikoloji Dergisi 1999; 14: 23-32
14. Guy W (Ed.) ECDEU Assessment Manual for Psychopharmacology. Publication 0ADM 76-338. US Department of Health, Education, and Welfare, Washington, DC 1976; s. 218-222
15. Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007; 22: 85-92
16. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007; 17: 138-144
17. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215-227
18. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting secondgeneration antipsychotic. J Clin Psychiatry 2003; 64: 1250-1257
19. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-1132
20. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084-1089
21. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005; 72: 249-258
22. Eerdekens M, Hove IV, Remmerie B, Mannaert E. Pharmacokinetic and tolerability of long acting risperidone in schizophrenia. Schizophr Res 2004; 70: 91-100
23. Cohen LJ. Risperidone. Pharmacotherapy 1994; 14: 253-265
24. Robinson D, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247